TW200605866A - Combination of bupropion and a second compound for affecting weight loss - Google Patents

Combination of bupropion and a second compound for affecting weight loss

Info

Publication number
TW200605866A
TW200605866A TW094126409A TW94126409A TW200605866A TW 200605866 A TW200605866 A TW 200605866A TW 094126409 A TW094126409 A TW 094126409A TW 94126409 A TW94126409 A TW 94126409A TW 200605866 A TW200605866 A TW 200605866A
Authority
TW
Taiwan
Prior art keywords
compound
bupropion
weight loss
individual
combination
Prior art date
Application number
TW094126409A
Other languages
English (en)
Inventor
Eckard Weber
Michael Alexander Cowley
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of TW200605866A publication Critical patent/TW200605866A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW094126409A 2004-08-03 2005-08-03 Combination of bupropion and a second compound for affecting weight loss TW200605866A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59855804P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
TW200605866A true TW200605866A (en) 2006-02-16

Family

ID=35124494

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094126409A TW200605866A (en) 2004-08-03 2005-08-03 Combination of bupropion and a second compound for affecting weight loss

Country Status (14)

Country Link
US (1) US20060058293A1 (zh)
EP (1) EP1773308A1 (zh)
JP (1) JP2008509142A (zh)
KR (1) KR20070083534A (zh)
CN (1) CN101001619A (zh)
AR (1) AR050600A1 (zh)
AU (1) AU2005271574A1 (zh)
BR (1) BRPI0514060A (zh)
CA (1) CA2576505A1 (zh)
IL (1) IL181086A0 (zh)
MX (1) MX2007001366A (zh)
RU (1) RU2007103313A (zh)
TW (1) TW200605866A (zh)
WO (1) WO2006017504A1 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
EP1505967B1 (en) * 2002-05-17 2016-07-13 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
KR20060128995A (ko) 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1748776A1 (en) * 2004-05-03 2007-02-07 Duke University Compositions for affecting weight loss
RU2007142346A (ru) * 2005-05-31 2009-07-20 Ориксиджен Серапьютикс, Инкорпорэйтд (Сша/Сша) (Us) Способы и составы для контроля психотических нарушений
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
ES2761812T3 (es) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20080027087A1 (en) * 2006-02-21 2008-01-31 Ampla Pharmaceuticals, Inc. CB1 antagonists and inverse agonists
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2668885C (en) * 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
ATE460925T1 (de) 2006-11-09 2010-04-15 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
EP2114150A4 (en) * 2007-02-01 2010-03-10 Alan I Green COMBINATIONS OF BLOCKING OF DOPAMINERGIC D2 RECEPTORS WITH INHIBITION OF NOREPINEPHRINE RECAPTATION AND BLOCKING OF NOREPINEPHRINE ALPHA RECEPTORS
US20090036426A1 (en) * 2007-07-30 2009-02-05 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
CA2725930A1 (en) * 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
WO2010045529A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100113583A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113604A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010151503A2 (en) * 2009-06-25 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010151565A2 (en) * 2009-06-26 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
WO2011009115A2 (en) * 2009-07-17 2011-01-20 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2011041632A2 (en) * 2009-10-01 2011-04-07 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
JP2015512945A (ja) * 2012-04-13 2015-04-30 バナー ファーマキャップス，インコーポレイティド 錠剤と液体または半固体の充填剤とを含む軟質弾性カプセル、ならびにそれらの製造方法
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
DE102013009114A1 (de) * 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
EP3615079A4 (en) * 2017-04-27 2020-09-23 Fresh Cut Development, LLC STABLE CANNABINOID FORMULATIONS
CN113069438A (zh) * 2021-04-01 2021-07-06 沈阳欣瑞制药有限公司 含有二甲双胍和安非他酮的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6110973A (en) * 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US20030144174A1 (en) * 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes

Also Published As

Publication number Publication date
RU2007103313A (ru) 2008-09-10
US20060058293A1 (en) 2006-03-16
CA2576505A1 (en) 2006-02-16
KR20070083534A (ko) 2007-08-24
MX2007001366A (es) 2007-04-02
AU2005271574A1 (en) 2006-02-16
AR050600A1 (es) 2006-11-08
CN101001619A (zh) 2007-07-18
EP1773308A1 (en) 2007-04-18
JP2008509142A (ja) 2008-03-27
IL181086A0 (en) 2007-07-04
BRPI0514060A (pt) 2008-05-27
WO2006017504A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
TW200605866A (en) Combination of bupropion and a second compound for affecting weight loss
HUS1700052I1 (hu) Opioid antagonistát és bupropiont tartalmazó készítmények súlyvesztés befolyásolására
ATE372121T1 (de) Nicht fermentiertes gelanteil aus samenhülsen von psyllium
EP2286838A3 (en) Treatment of obesity and related disorders
NO20054343L (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
MX2010005331A (es) Composiciones y metodos para tratamiento de purpura.
NO20072839L (no) 4-hydroksybenzomorfaner
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
WO2008039863A3 (en) Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders
MX2010010726A (es) Composicion de estilizado de cabello.
TW200602076A (en) O, O'-amidomalonate and N, O-amidomalonate platinum complexes
DE60308915D1 (de) Kombination aus beta-2-adrenozeptor-agonisten und aminozuckern und ihre verwendung zur behandlung von immunmodulatorischen erkrankungen
BRPI0412715A (pt) células precursoras de oligodendrócitos e métodos de obter e cultivar as mesmas
IT1306173B1 (it) Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare.
WO2001055107A3 (en) Aromatic amines and amides acting on the melanocortin receptors
GB2390366A (en) M tuberculosis chaperonin 10 and uses thereof
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
Moreno Orpheus in hell: Music and therapy in the Holocaust.
EP1854470B8 (en) Method of treating inflammation disorders using extracts of passion fruit
AU2003268235A8 (en) Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
TW200503717A (en) Substituted 1,4-pyrazine derivatives
NL300918I2 (nl) Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride
ATE248709T1 (de) Verbundelemente
WO2006028631A3 (en) Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin 4-receptor agonists